In conclusion, NGS of cfDNA is useful not only for the detection of ALK fusions and resistance mutations, but also for assessing prognosis and monitoring the dynamic changes of genomic alterations in ALK positive NSCLC treated with ALK‐TKI. The gene discussed is ALK; the disease is non-small cell lung carcinoma.